Illinois Municipal Retirement Fund Raises Position in Jazz Pharmaceuticals PLC $JAZZ

Illinois Municipal Retirement Fund increased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 26.7% during the first quarter, HoldingsChannel reports. The firm owned 61,883 shares of the specialty pharmaceutical company’s stock after acquiring an additional 13,057 shares during the period. Illinois Municipal Retirement Fund’s holdings in Jazz Pharmaceuticals were worth $11,699,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also bought and sold shares of the company. Royal Bank of Canada increased its position in Jazz Pharmaceuticals by 96.5% in the first quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock worth $8,394,000 after buying an additional 33,210 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Jazz Pharmaceuticals by 147.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after acquiring an additional 209,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Jazz Pharmaceuticals by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock worth $24,479,000 after acquiring an additional 7,954 shares during the period. Focus Partners Wealth increased its holdings in Jazz Pharmaceuticals by 3.4% in the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock worth $574,000 after acquiring an additional 154 shares during the last quarter. Finally, Geneos Wealth Management Inc. raised its stake in Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Truist Financial dropped their price objective on shares of Jazz Pharmaceuticals from $256.00 to $254.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Wells Fargo & Company lifted their target price on shares of Jazz Pharmaceuticals from $265.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday. Barclays boosted their price target on shares of Jazz Pharmaceuticals from $253.00 to $260.00 and gave the company an “overweight” rating in a research report on Tuesday. Royal Bank Of Canada upped their price target on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $245.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, May 7th. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $256.44.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, Director Rick E. Winningham sold 2,741 shares of the stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $241.57, for a total value of $662,143.37. Following the sale, the director directly owned 9,567 shares in the company, valued at $2,311,100.19. This represents a 22.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Heather Ann Mcsharry sold 2,000 shares of the firm’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $241.00, for a total transaction of $482,000.00. Following the completion of the transaction, the director directly owned 18,449 shares of the company’s stock, valued at approximately $4,446,209. The trade was a 9.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 13,098 shares of company stock valued at $3,131,906 in the last three months. Insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Stock Up 1.2%

Shares of NASDAQ JAZZ opened at $242.18 on Friday. Jazz Pharmaceuticals PLC has a 52 week low of $105.00 and a 52 week high of $250.49. The business has a 50-day simple moving average of $234.67 and a two-hundred day simple moving average of $200.09. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. The company has a market cap of $15.21 billion, a P/E ratio of -12,102.95, a P/E/G ratio of 0.21 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The firm had revenue of $1.07 billion for the quarter. Research analysts anticipate that Jazz Pharmaceuticals PLC will post 21.9 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.